Europe: the definition and epidemiology of late presentation, its medical and societal consequences, the need for earlier HIV testing and strategies for management of late-presenting patients. Each topic is discussed in detail here. A concluding article presents recommendations in each topic that were developed at the meeting to address the continuing challenge represented by late presentation for HIV treatment.
In the three decades since the start of the AIDS epidemic, medical and scientific advances in the understanding and treatment of the disease have been substantial. Today, as our understanding of HIV type-1 (HIV-1) infection and its management expands, and the risk-benefit ratios of available drug regimens tip further in favour of benefit, international guidelines for the management of HIV-1 are shifting towards earlier initiation of treatment [1] [2] [3] [4] . Such shifts in thinking are beneficial for those who are identified and diagnosed early.
However, by current definitions, many patients still present late after infection. Across Europe, between 15% and 38% of those infected with HIV do not present for testing until late in infection, when their CD4 + T-cell counts are low, viral load high and their immune system has been significantly compromised [5] . The negative consequences of late presentation are serious, both for the patient in terms of increased morbidity and mortality, for healthcare systems in terms of the resulting resource burden, and the community in terms of HIV disease transmission [6, 7] .
This publication is based on the proceedings of a meeting of a European working group of HIV experts convened in Windsor, UK, in March 2009. It provides an overview of four key issues for late presentation in Europe: the epidemiology, consequences, earlier testing and management of late presenters.
Johnson et al. [8] assess the prevalence of late presentation in Europe. Late presentation appears to be common in all patient groups, but precise data of the sort needed to answer key clinical questions -for example, to compare the situation in different European countries or within a country over time -are scarce [8] . If progress in reducing late presentation is to be measured accurately, a clear definition is required; however, no standard definition currently exists. Definitions used in clinical trials encompass a range of CD4 + T-cell counts at presentation (typically <50, 200 or 350 cells/µl) and other conditions (such as AIDS diagnosis within 3 or 6 months of HIV diagnosis) [5] .
Moreno et al. [9] describe the medical and societal consequences for patients who present late compared with those who present early. Lower CD4 + T-cell counts at presentation are strongly associated with a higher probability of progression to death [10] ; late presenters are also at higher risk for specifically short-term mortality [6] . Other consequences include a higher risk of clinical events, higher risk of treatment-related adverse events, increased risk of infecting other individuals and greater resource use during treatment [9] . Minimizing late presentation with HIV infection should therefore be a public health priority. 
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Yazdanpanah et al. [11] examine what is known about HIV testing strategies across Europe and suggest that improvements are needed in many areas. At present, there is substantial variation in practice in different European countries and little comparison of the most effective strategies [12] . Broader criteria for routine testing and careful selection of the most effective screening programmes are essential.
Rockstroh et al. [13] review the options for managing patients who present late with HIV infection and describe considerations that might be particularly important in this complex group. Morbidity and mortality are worsened in these patients, which in itself increases the risks of ineffective antiretroviral therapy (ART) [6] . These patients are also more likely to have concomitant conditions whose management must be carefully coordinated with ART, such as opportunistic infection or cancer, and face an increased risk of toxicities during ART exposure [6] .
Finally, we present recommendations in the context of each of the above four areas together with an assessment of their utility across Europe [14] . These recommendations were developed at the same meeting described above.
Despite important work helping to improve the frequency of early testing by organizations such as HIV in Europe [15] , late presentation for HIV remains a considerable problem. The consequences of late presentation are numerous, both for society and for individuals, and further strategies to encourage and facilitate earlier diagnosis are needed. Many factors need to be considered when determining an appropriate, individualized treatment strategy for patients who present late. Perhaps in the future, armed with greater resources to encourage early diagnosis and initiation of treatment, and a better understanding of the role of current and future therapies, we will be able to improve prognosis for all patients with HIV infection.
